The prevalence of allergic, neurodevelopmental, and autoimmune conditions was similar between children born to anti-Ro antibody-positive mothers vs the general population. Children born to anti-Ro ...

To the Technical Assistance and Rural Extension Association of the State of Rondônia (EMATER-RO) for technical support ... et al. Prevalence of anti- antibodies in cattle and dogs from Western Amazon, ...

BriaPro plans on developing anti-B7-H3 antibodies for multiple cancer indications and plans to incorporate them into its Bria-TILsRx™ platform—a proprietary antibody platform designed to ...

Objective Anti ... the Ro/La system, a heterogeneous antigenic complex constituted by three different proteins: Ro 52 kD, Ro 60 kD and La. In addition to indirect immunofluorescence staining, ...

using a systematic chart formulated after consensus between the participating centres. All patients were tested for different anti-dsDNA antibody specificities with assays habitually used in each ...

Introduction: The clinical characteristics of patients positive for anti-small ubiquitin-like modifier 1 ... 2.5 AtheNA Multi-Lyte ANA-II plus test system Antiextractable nuclear antibodies (ENA: ...

More information: Emmanouil Papasavvas et al, Cloning and Functional Characterization of Novel Human Neutralizing Anti–IFN-α and Anti–IFN-β Antibodies, The Journal of Immunology (2024). DOI ...

More information: Ryota Sada et al, Newly developed humanized anti‐CKAP4 antibody suppresses pancreatic cancer growth by inhibiting DKK1‐CKAP4 signaling, Cancer Science (2024). DOI: 10.1111 ...

Research suggests including anti-SSA antibodies in routine clinical practice could notably improve the risk stratification of patients with SSc In a study of the EUSTAR database of established ...

VIENNA — Anti-Ro/SSA antibodies may help predict which patients with systemic sclerosis (SSc) are at a greater risk for interstitial lung disease (ILD) and may serve as a biomarker to guide ...

Anti-PD-1/TGF-βRII bispecific antibody fusion protein LBL-015 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose-escalation study. This is an ASCO ...